The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes
Open accessAbstract
A nonenzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules and subsequently alters their structural integrity and function. This process has been known to progress at an accelerated rate under hyperglycemic and/or oxidative stress conditions. Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent and senescent macroprotein derivatives termed advanced glycation end products (AGEs). There is a growing body of evidence indicating that interaction of AGEs with their receptor (RAGE) elicits oxidative stress generation and as a result evokes proliferative, inflammatory, thrombotic and fibrotic reactions in a variety of cells. This evidence supports AGEs' involvement in diabetes- and aging-associated disorders such as diabetic vascular complications, cancer, Alzheimer's disease and osteoporosis. Therefore, inhibition of AGE formation could be a novel molecular target for organ protection in diabetes. This report summarizes the pathophysiological role of AGEs in vascular complications in diabetes and discusses the potential clinical utility of measurement of serum levels of AGEs for evaluating organ damage in diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“Prospective Diabetes Study (UKPDS), called UKPDS80, has also shown that benefits of an intensive therapy in patients with type 2 diabetes are sustained after the cessation of the trial (18).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Self-citationDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S.-I., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11771 · Cited by 475
Self-citationAssociation between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) · Diabetes · doi:10.2337/db14-0930 · Cited by 333
Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond
Daffu, G., Del Pozo, C., O'Shea, K., Ananthakrishnan, R., Ramasamy, R., & Schmidt, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141019891 · Cited by 222
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Cai, W., He, J. C., Zhu, L., Peppa, M., Lu, C., Uribarri, J., & Vlassara, H. (2004) · Circulation · doi:10.1161/01.cir.0000135587.92455.0d · Cited by 177
Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.007 · Cited by 148
Self-citationTahara, N., Yamagishi, S., Matsui, T., Takeuchi, M., Nitta, Y., Kodama, N., Mizoguchi, M., & Imaizumi, T. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00177.x · Cited by 116
Self-citationNakashima, S., Matsui, T., Takeuchi, M., & Yamagishi, S.-I. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1371892 · Cited by 90
Self-citationNakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Ueda, Y., Suzuki, T., Yamada, S., Takeuchi, M., Fukami, K., Ueda, S., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.018 · Cited by 53
Self-citationNakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Suzuki, T., Ueda, Y., Yamada, S., Shoji, H., Takeuchi, M., Ueda, S., et al. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.05.002 · Cited by 46
Self-citationReceptor for advanced glycation endproducts and progressive kidney disease
Fukami, K., Taguchi, K., Yamagishi, S.-I., & Okuda, S. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000091 · Cited by 46 · cited 1×
“Diabetic Nephropathy Accumulation of AGEs in the kidney may contribute to the progressive alteration in renal architecture and loss of renal function in patients and rodents via various mechanisms, including their cross-linking properties of matrix proteins and activation of the downstream signaling (2,66,67).”
BackgroundSelf-citationShort-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells
Yamamoto, Y., Yonekura, H., Watanabe, T., Sakurai, S., Li, H., Harashima, A., Myint, K. M., Osawa, M., Takeuchi, A., Takeuchi, M., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.030 · Cited by 44
Cited by
Pisoschi, A. M., Pop, A., Iordache, F., Stanca, L., Predoi, G., & Serban, A. I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112891 · Cited by 816
The role of vasculature in bone development, regeneration and proper systemic functioning
Filipowska, J., Tomaszewski, K. A., Niedźwiedzki, Ł., Walocha, J. A., & Niedźwiedzki, T. (2017) · Angiogenesis · doi:10.1007/s10456-017-9541-1 · Cited by 559
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
Shen, C.-Y., Lu, C.-H., Wu, C.-H., Li, K.-J., Kuo, Y.-M., Hsieh, S.-C., & Yu, C.-L. (2020) · Molecules · doi:10.3390/molecules25235591 · Cited by 301
Beneficial Effects of Citrus Flavonoids on Cardiovascular and Metabolic Health
Mahmoud, A. M., Hernández Bautista, R. J., Sandhu, M. A., & Hussein, O. E. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5484138 · Cited by 298
Metadata
- Authors
- Yamagishi, S.-I., Nakamura, N., Suematsu, M., Kaseda, K., & Matsui, T.
- Venue
- Molecular Medicine
- Published
- 2015-01
- Volume
- 21
- Issue
- S1
- Pages
- S32-S40
- ISSN
- 1076-1551 (ISSN-L)
- 1528-3658
- OpenAlex
- W2176343920
- Cited by
- 173
- References
- 22
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.